Stellar Biotechnologies (SBOT) Stock Price, News & Analysis

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Key Stats

• Today's Range: $6.23 to $7.35
• 50-Day Range: $4.44 to $298,098.00
• 52-Week Range: $0.75 to $3.25
• Volume: 6.72 million shs
• Average Volume: 2.95 million shs
• Market Capitalization: $37.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SBOT Stock Analysis - Frequently Asked Questions

How were Stellar Biotechnologies' earnings last quarter?

Stellar Biotechnologies Inc (NASDAQ:SBOT) announced its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. Stellar Biotechnologies had a negative trailing twelve-month return on equity of 51.12% and a negative net margin of 1,782.64%.

When did Stellar Biotechnologies' stock split?

Stellar Biotechnologies's stock reverse split before market open on Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Stellar Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stellar Biotechnologies investors own include NightHawk Biosciences (NHWK), NexGen Energy (NXE), XOMA (XOMA), Anavex Life Sciences (AVXL), EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK) and Rigel Pharmaceuticals (RIGL).

Company Calendar

• Last Earnings: 5/08/2019
• Today: 5/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SBOT
• CIK: 1540159
• Web: www.stellarbiotechnologies.com
• Phone: 805-488-2800
• Fax: N/A
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,030,000.00
• Net Margins: -1,782.64%
• Pretax Margin: N/A
• Return on Equity: -51.12%
• Return on Assets: -48.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.24
• Quick Ratio: 8.96

Sales & Book Value

• Annual Sales: $210,000.00
• Price / Sales: 178.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.12 per share
• Price / Book: 3.33

Miscellaneous

• Outstanding Shares: 5,330,000
• Free Float: N/A
• Market Cap: $37.58 million
• Optionable: Not Optionable
• Beta: N/A